나눔터
공지사항
의학정보
복지정책
환우회소식
회비 및 후원금 납부내역
헌팅턴병 메뉴얼
HOME > 나눔터 > 의학정보

작성자
huntington [작성일 : 2016-09-23 15:48:40 ]   
제목 Teva 제약회사에서 진행중인 임상시험 소식을 전해드립니다.

신경보호효과 개선을 위한 약(Pridopidine)으로 현재 2임상시험 중에 있으며 헌팅턴병 증상을 늦추는 효과를 보인다고 합니다.


아직은 임상시험 단계인 약이며 추가 임상시험 단계등의 결과나오면 소식전해드리겠습니다.





Trial finds Teva drug could slow Huntington's disease

 

http://www.globes.co.il/en/article-teva-pridopidine-could-slow-huntingtons-d

isease-1001153229

 

Globes Correspondent 09/19/2016

 

 

 

Teva Pharmaceutical Industries Ltd. <http://www.tevapharm.com/>  today

announced what could be a major breakthrough in the treatment of

Huntington's Disease (HD) with positive results from its exploratory Phase

II PRIDE-HD study. The trial found a statistically significant impact on the

endpoint of the progression of Huntington Disease at 52 weeks following

treatment with Pridopidine at certain doses versus placebo. The effect of

Pridopidine was further evident in a sub-population of patients with early

stage HD, an effect first observed at 26 weeks.

 

 

 

"Slowing down the progression of this disease has proven to be impossible

until now. These findings give us a reason to believe we may be finally

making progress in slowing deterioration of disease," said Spyros

Papapetropoulos, Teva's VP Clinical Development, Neurodegenerative Diseases.

 

 

 

 

This was a 52-week, dose-ranging trial of Pridopidine twice daily versus

placebo, in the treatment of Huntington disease (HD). The study was directed

at measuring improvement in motor function and the effect on HD progression.

An unusually high placebo effect, extending beyond that expected from

previous studies, limited the ability to determine treatment effects on

assessments of HD motor scores. Evidence of symptomatic impact, however, was

seen in the early stage HD patient sub-population, with improvement in Total

Motor Score (TMS) and dystonia observed at 26 and 52 weeks in this patient

sub-set (stage 1 HD) at specific doses.

 

 

 

The discovery of Pridopidine's previously unknown mode of action as a potent

agonist of the Sigma 1 Receptor (S1R) resulted in a change in PRIDE-HD study

design, from a 26-week study focused on symptoms, to a 52-week study focused

on exploring pridopidine's potential impact on disease progression, as

measured by Total Functional Capacity (TFC).

 

 

 

"I am encouraged by these results, which provide us with clear insights into

the approach to be taken in Phase III development", said Michael Hayden,

President of Teva Global R&D and Chief Scientific Officer. "My obvious hope

is that this will provide the HD community with a medicine capable of

slowing down the progression of this devastating disease."

 

 

 

"These study results are very important for the HD community and for the

continued development of pridopidine. Firstly, pridopidine's safety profile

has been confirmed and extended. Secondly, we now have a clearer idea of the

dosages to study in Phase 3. Lastly, we have some of the most encouraging

evidence to date about an intervention which may slow the inexorable

functional decline of HD," said Karl Kieburtz, M.D., M.P.H., Director of the

Clinical & Translational Science Institute at the University of Rochester

Medical Center.

 

 

 

The results seen in this exploratory study will need to be confirmed in a

Phase III program that will be developed in collaboration with relevant

regulatory agencies.

 

 

 

Pridopidine is an investigational, oral small molecule being developed for

the treatment of HD that exerts its effect as an agonist of S1R. S1R plays a

key role in neuroprotection through increased production of brain-derived

neurotrophic factor (BDNF). Levels of BDNF are decreased in HD and other

neurodegenerative disorders including Parkinson's disease, Alzheimer's

disease and ALS.

 

================================

 

 

 

Huntington Study Group PRIDE HD Study Information:

http://huntingtonstudygroup.org/current-clinical-trials/pride-hd-study/

 

.       No information available yet on enrolling for the Phase 3 study.

 

.       No facilities in Florida participated in the Phase II study:

https://clinicaltrials.gov/ct2/show/study/NCT02006472?show_locs=Y#locn

 

[ 새글 | 답글 | 수정 | 삭제 ] [ 목록 ]
[ 총게시물 : 37 | page : 2 ]
[ 정렬조건 : 등록일 | 조회  ]
순번 제목 조회 파일 등록일 작성자
37   헌팅틴 낮추기 임상시험에 대한 전문가와의 질의 응답 627 18/01/03 운영자  
36   ASO 약물이 헌팅턴 질환 환자의 돌연변이 단백질 수준 감소시키는데 성 556 17/12/18 운영자  
35   건강한 huntingtin 단백질을 제거하여 그 기능을 이해하는 연구 (HDBuz 479 17/11/07 운영자  
34   정밀한 헌팅틴-돌연변이 단백질을 표적으로 하는 헌팅틴을 낮추는 약물 333 17/09/01 운영자  
33   유전자 편집을 위한 진일보: CRISPR-Cas9 와 헌팅턴병 (HDBuzz) 310 17/08/18 운영자  
32   HDBuzz 소식을 올립니다. 477 17/07/13 운영자  
31   헌팅턴병 무도병 완화약 FDA 승인에 대한 HDBuzz 글 올립니다. 619 17/04/17 운영자  
30   HDBuzz 소식을 올립니다. 494 17/03/19 운영자  
29   헌팅틴 단백질의 발달과정 역할 규명에 대한 HDBuzz 글이 올라왔습니다 500 17/02/21 운영자  
28   HDBuzz 소식입니다. 471 17/01/18 운영자  
27   수면과 헌팅턴병에 대한 기사글 올립니다. 523 16/12/13 운영자  
26   PRIDE-HD 임상시험에서 Pridopidine의 효과에 대하여 947 16/12/03 운영자  
25   유전자 치료 동향 정보글 올립니다. 486 16/11/07 운영자  
24   Teva 제약회사에서 진행중인 임상시험 소식을 전해드립니다. 569 16/09/23 운영자  
23   줄기세포 연구 소식 "혈액에서 배양한 줄기세포로 ‘중뇌’ 개발" 올립 549 16/08/02 운영자  
22   헌팅턴병 증상완화 신약관련 글 올립니다. 3443 16/07/13 운영자  
21   헌팅턴병 임상시험 현황과 상황에 대해 설명한 논문한편 올립니다. 922 16/05/09 운영자  
20   헌팅턴병 약물 개발 기사글 올립니다. 880 16/03/26 운영자  
19   헌팅턴병 동물에서 사람의 줄기세포를 이용한 성공적 치료 결과에 대한 1007 16/03/25 운영자  
18   헌팅턴병 치료 약물 연구개발에 대한 소개글 올립니다. 565 16/03/07 운영자  

1 2 [ 새글 | 처음목록 | 목록 ]  
단체명 : 헌팅턴병 환우회   주소 : 서울시 종로구 연건동 서울대학교병원 CMI  
TEL : 02-747-4423   FAX : 02-747-4423  
Copyrightⓒ by huntington.co.kr All rights reserved.    webmaster  개인정보 취급방침